Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) just unveiled an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has issued a supplementary announcement regarding its 2026 R&D-related Goods Framework Agreement, under which it procures research and development-related materials from connected party China Resources Kelun and its subsidiaries. The company confirmed that no transactions occurred under this framework between January 1 and 16, 2026, and detailed a pricing policy designed to ensure all such connected transactions are conducted on normal commercial terms, including arm’s length negotiations, benchmarking against independent suppliers, and reference to prevailing market prices and production costs. To safeguard minority shareholders and align with regulatory expectations on connected transactions, the company will compare quotes with at least two independent third parties, subject proposed terms to internal audit review and oversight by the audit committee, and require approval from senior management before finalizing prices, underscoring its efforts to demonstrate transparency and fair pricing in related-party procurement.
The most recent analyst rating on (HK:6990) stock is a Buy with a HK$545.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.
More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a Hong Kong-listed biopharmaceutical company focused on research and development activities, procuring specialized R&D-related goods and services to support its drug development operations in the People’s Republic of China and international markets.
Average Trading Volume: 631,919
Technical Sentiment Signal: Buy
Current Market Cap: HK$103.2B
For a thorough assessment of 6990 stock, go to TipRanks’ Stock Analysis page.